Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.

ABSTRACT:

Background

Immunotherapies targeting cellular immunity are currently approved for treatment of melanoma, renal cell carcinoma, and prostate cancer. Studies on the immunogenicity and immune responsiveness of pediatric tumors are limited, therefore, it remains unclear to what extent T-cell-based immunotherapy holds promise for pediatric solid tumors.

Procedure

A new rhabdomyosarcoma cell line (M3-9-M) was derived from an embryonal rhabdomyosarcoma (ERMS) occurring in a C57BL/6 mouse transgenic for hepatocyte growth factor and heterozygous for mutated p53. Primary tumors and metastases derived from M3-9-M were studied for similarities to human ERMS, and for immunogenicity and immune responsiveness.

Results

Primary and metastatic tumors develop after orthotopic injection

SUBMITTER: Meadors JL 

PROVIDER: S-EPMC7401311 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature